about
Redox regulation in amyotrophic lateral sclerosisScreening of Drugs Inhibiting In vitro Oligomerization of Cu/Zn-Superoxide Dismutase with a Mutation Causing Amyotrophic Lateral SclerosisSelected statins produce rapid spinal motor neuron loss in vitro.Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.Statins and amyotrophic lateral sclerosis--the level of evidence for an association.Emerging drugs for amyotrophic lateral sclerosis.Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis.Nutrition management of amyotrophic lateral sclerosis.Systems pharmacology modeling: an approach to improving drug safety.AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis.Atorvastatin Protects NSC-34 Motor Neurons Against Oxidative Stress by Activating PI3K, ERK and Free Radical Scavenging.Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial.Prior medical conditions and the risk of amyotrophic lateral sclerosis.Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice.Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.Energy metabolism in ALS: an underappreciated opportunity?
P2860
Q27026894-9C9ED32E-F8E6-4AE7-8AFC-82391E7B645EQ28831086-7A7C1E4C-0DEB-49C0-A092-714B2D526AF1Q34306372-507352EB-3F6C-4F25-B39D-7C0A3822BE1CQ35630224-B6FE3A03-E75B-4A96-987E-175A4CBB6406Q37636347-98D46CA5-E2FD-45D7-BC67-22D24AE98418Q37909351-5B60A449-DB8D-4DE5-B060-0E7338024CEBQ38020536-4C078715-346B-49C0-BCCB-572262EAE356Q38058378-F967CFA3-9A28-46E4-9E64-F67813AF5738Q38087150-1E76EBAA-AEEB-4123-9A97-26BE269C5C4BQ38153621-F1CD486C-C2F7-422A-8E61-D093A788F484Q38552413-4B17714E-8BA3-4934-A173-0550C9ED69E1Q38921294-0505A180-AEDC-49AB-8585-9205B81DECC6Q40957672-89DDBCD9-4308-44D7-BF54-996B0E27B9C9Q41597318-BC04DFA6-0856-49C2-A8D7-56E84EA4F2F8Q42673812-EB1AA558-232D-4B17-B767-EF813DEE3CFEQ43239618-DF42CBAE-64E2-4642-8432-450C02C1E667Q49335981-6EECF59F-4A4C-4811-A725-99F2D4709E29Q52651163-378D3F5B-484A-441A-B9B3-D1C0D8D906E8
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Are statin medications safe in patients with ALS?
@en
Are statin medications safe in patients with ALS?
@nl
type
label
Are statin medications safe in patients with ALS?
@en
Are statin medications safe in patients with ALS?
@nl
prefLabel
Are statin medications safe in patients with ALS?
@en
Are statin medications safe in patients with ALS?
@nl
P2093
P2860
P1476
Are statin medications safe in patients with ALS?
@en
P2093
Dan Patton
Lorne Zinman
Marek Gawel
Reza Sadeghi
P2860
P304
P356
10.1080/17482960802031092
P577
2008-08-01T00:00:00Z